The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors

By Choi Brian   Alberti Dona   Schelman William   Kolesar Jill   Thomas James   Marnocha Rebecca   Eickhoff Jens   Ivy S.   Wilding George   Holen Kyle  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 5, 2010-10 ,pp. : 973-980

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

By Yen Yun   Margolin Kim   Doroshow James   Fishman Mayer   Johnson Bonny   Clairmont Caroline   Sullivan Dan   Sznol Mario  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 4, 2004-10 ,pp. : 331-342

Springer Publishing Company

Access to resources Recommend Favorite

Apoptosis of lymphocytes in peripheral blood of patients with melanoma

By Tas Faruk   Duranyildiz Derya   Argon Andac   Oguz Hilal   Camlica Hakan   Yasasever Vildan   Topuz Erkan  

Medical Oncology, Vol. 22, Iss. 2, 2005-06 ,pp. : 177-181

Humana Press, Inc

Access to resources Recommend Favorite

Evaluation of Gefitinib for Treatment of Refractory Solid Tumors and Central Nervous System Malignancies in Pediatric Patients

By Freeman Burgess   Daw Najat   Geyer J.   Furman Wayne   Stewart Clinton  

Cancer Investigation, Vol. 24, Iss. 3, 2006-05 ,pp. : 310-317

Informa Healthcare

Access to resources Recommend Favorite

Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

By Campone M.   Isambert N.   Bourbouloux E.   Maury S.   Monin-Baroille P.   Berille J.   Fumoleau P.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 689-695

Springer Publishing Company

Access to resources Recommend Favorite